Most Favored Nation Drug Price Deals Stay Secret, Burning Questions Remain

Chris Klomp, a key architect of the administration’s Most-Favored Nation (MFN) drug pricing policy, faced back-to-back U.S. Senate confirmation hearings for Deputy HHS Secretary. The MFN plan aims to align U.S. drug prices with those in other wealthy countries, but deals reportedly made with 26 pharmaceutical companies remain confidential, leaving lawmakers unable to verify how much federal and state governments—and patients—will save. Klomp said the secrecy is needed to protect trade secrets and that only the “framework” principles are public. Senators questioned what companies received in return, including during Medicaid pricing, and raised concerns about the lack of transparent international net price data and specific drug selections and discounts.